Zanubrutinib combined regimens for treatment of elderly patients with central nervous system lymphoma: report of 3 cases and review of literature
10.3760/cma.j.cn115356-20220403-00095
- VernacularTitle:含泽布替尼联合方案治疗老年中枢神经系统淋巴瘤患者3例并文献复习
- Author:
Xiao YU
1
;
Baozhi FANG
;
Muzhi YUAN
;
Yifei ZHOU
;
Qiudan SHEN
;
Ming'en LYU
Author Information
1. 南京医科大学附属苏州医院血液科，苏州 215002
- Keywords:
Lymphoma;
Central nervous system neoplasms;
Antineoplastic combined chemotherapy protocols;
Zanubrutinib;
Aged
- From:
Journal of Leukemia & Lymphoma
2022;31(9):539-543
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of zanubrutinib combined regimens for treatment of elderly patients with central nervous system lymphoma (CNSL).Methods:The clinical data of 3 elderly patients with CNSL who received zanubrutinib combined regimens from July 2020 to March 2022 in the Affiliated Suzhou Hospital of Nanjing Medical University were retrospectively analyzed. Two of them were primary central nervous system lymphoma (PCNSL) and one was secondary central nervous system lymphoma (SCNSL). Relevant literature was reviewed at the same time.Results:The two patients with PCNSL were treated with zanubrutinib in combination with rituximab and lenalidomide (Z-R 2) regimen. One of them achieved complete remission (CR) after 6 cycles, and the other patient achieved partial remission (PR) after 1 cycle of Z-R 2 regimen. The patient with SCNSL was diagnosed with diffuse large B-cell lymphoma (DLBCL) previously and suffered from central nervous system relapse after achieving CR. The patient achieved PR after 2 cycles of Z-R 2 regimen, and then achieved CR followed by 4 cycles of zanubrutinib in combination with rituximab and high-dose methotrexate (Z-R-HD-MTX) regimen. Two of the three patients were still in CR until April 2022, and the longest disease-free survival time was 15 months. There were no severe adverse reactions during the treatment. Conclusions:Zanubrutinib combined regimens for 3 elderly patients with CNSL have shown promising effect and well tolerance, which may be considered as novel treatment for CNSL patients who are unable to tolerate severe chemotherapies or autologous hematopoietic stem cell transplantations.
